Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

Lexaria Announces Name Change of PoViva Tea to ViPova(TM) Tea, and Provides Information on Hemp-Based Industry

Posted by AGORACOM-JC at 11:14 AM on Wednesday, December 17th, 2014

Kelowna, British Columbia–(December 17, 2014) – Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) announces that, effectively immediately, it’s 51%-owned company formerly known as PoViva Tea, will now operate with the trade name of ViPovaâ„¢ Tea. Selling our products under the name of ViPovaâ„¢ is a branding strategy undertaken to ensure long term protection of intellectual rights.

The name change does not affect ownership, operational or any other material issues. However the name change has delayed the product launch by 1-2 weeks, so that ViPovaâ„¢ Tea is now expected to be available to be ordered by consumers around the first week of January.

Both Lexaria and ViPovaâ„¢ also wish to clarify some important distinctions about the Cannabidiol(CBD)-from-hemp industry within which ViPovaâ„¢ operates. Hemp based CBD is legal in all 50 states, as are hemp-based food products that can be purchased from national retailers like Whole Foods or Costco, and many regional food stores. Popular hemp food products include hemp cereal, seeds, milk, and oil.

Hemp based products contain very low thresholds of Tetrahydrocannabinol (THC) below government-imposed limits of less than 0.3%. At the same time, the CBD within hemp is NOT psychoactive and does not create feelings of euphoria. Hemp is grown legally in countries like Canada, England, New Zealand and parts of Europe, and is legally imported into the USA from these and other countries.

ViPovaâ„¢ uses only legal CBD oil extracts, grown from legal hemp in nations where it is legal to do so, in ViPovaâ„¢-branded tea. ViPovaâ„¢ uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPovaâ„¢ has this ground-breaking technology for CBD/lipid infusion.

ViPovaâ„¢ has not entered, and has no plans to enter, the medical marijuana market whether located within the USA or in any other country. ViPovaâ„¢ is building a new company and product line focused exclusively on legal CBD products, which at this time are available only within the United States.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that any cannabinoid-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). ViPovaâ„¢ products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Tags: , , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Announces Name Change of PoViva Tea to ViPova(TM) Tea, and Provides Information on Hemp-Based Industry

Mazorro Provides Update on GrowPros MMP Activities

Posted by AGORACOM-JC at 8:36 AM on Wednesday, December 17th, 2014

OTTAWA, ONTARIO–(Dec. 17, 2014) – Mazorro Resources Inc. (the “Company“) (CSE:MZO)(FRANKFURT:JAM) announces that, further to its press release November 6, 2014 announcing the signature of a definitive agreement with GrowPros MMP Inc. (“GrowPros“) and in anticipation of a successful closing of the proposed amalgamation (“Amalgamation“), management of GrowPros has provided the following update on its activities.

GrowPros is finalizing the second revision to its application for a license under the Marihuana for Medical Purposes Regulations (“MMPR“). These revisions are part of the normal review process and GrowPros is impressed by the expediency with which its file has been reviewed by Health Canada. In addition, GrowPros will be closing the previously-announced transaction for the purchase of 190 acres of agricultural land located 45 minutes North of Ottawa, Ontario which will house a 50,000 sq. ft. production facility with unlimited room for expansion. As a result, management of GrowPros advises that it expects to receive a ready to build authorization from Health Canada in the second quarter of 2015.

GrowPros also reports that it is currently in preliminary negotiations with companies in various service and supply segments of the cannabis production industry. Management of GrowPros advises that merging main stream business into the cannabis industry will be a major focus of GrowPros going forward. Accordingly, these opportunities should provide a higher return on investment for GrowPros and, ultimately, a quicker route to profitability than solely being an applicant or licensed MMPR producer. This is in line with GrowPros‘ philosophy as a medical marihuana consultation and acquisition firm.

As previously announced on December 3, 2014, the Company would like to remind shareholders that the special meeting of the Company’s shareholders to approve the (i) proposed change of business from mineral resource exploration to the medical marijuana industry and (ii) change of name to “GrowPros Cannabis Inc. / Entreprise GrowPros cannabis inc.” will be held on December 29, 2014 (the “Special Meeting“). A notice of meeting, management information circular, and form of proxy in respect of the Special Meeting has been sent to shareholders and is available under the Company’s profile on the CSE website and on SEDAR.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to complete the Amalgamation and change of business, failure to obtain sufficient financing, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Any forward-looking statement speaks only as of the date on which it is made and except as may be required by applicable securities laws. The Company disclaims any intent or obligation to update any forward-looking statement.

Mazorro Resources Inc.
André Audet
Interim President, CEO, and CFO
(613) 241-2332

Tags: , , , , ,
Posted in GrowPros Cannabis Inc., Medical Marijuana Stocks | Comments Off on Mazorro Provides Update on GrowPros MMP Activities

Supreme Pharmaceuticals Completes Upgrades on Marijuana Greenhouse Facility and Awaits Pre-License Inspection by Health Canada – Video News Alert on InvestmentPitch.com

Posted by AGORACOM-JC at 11:08 AM on Monday, December 15th, 2014

Vancouver, British Columbia–(December 15, 2014) – Supreme Pharmaceuticals (CSE:SL) (OTC PINK: SPRWF), announced the completion of security and infrastructure upgrades at its hybrid greenhouse facility located in southern Ontario, and awaits pre-license inspection by Health Canada. The 342,000 square foot greenhouse, purchased in May 2014, is located in Kincardine.

InvestmentPitch.com has produced a “video news alert” which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter “Supreme” in the search box.

The company has spent approximately $4 million in upgrades to transform the out-of-use tomato greenhouse into a highly secured, state-of-the-art, automated marijuana facility. These upgrades include a level 9 security vault capable of storing up to $150 million of dried marijuana, a sophisticated digital security system including intrusion detection and visual surveillance, along with sanitation and automation systems, all of which have been designed and installed to meet or exceed regulatory requirements set by Health Canada.

The company and its management team have carefully planned the upgrades to provide an optimal environment to manufacture high quality, low-cost medical marijuana. If successful in obtaining the license to produce medical marijuana subsequent to the pre-license inspection, the company expects to immediately commence growing in its first completed phase of the Facility. Subsequent phases of the facility are expected to be built out later in 2015 which will increase the productive capacity of the facility.

John Fowler, Director of Operations, stated: “The construction thus far has been a massive undertaking for us. We are excited to move forward in the licensing process and stay on track with our goal of providing high-quality, low-cost medical marijuana in the coming months.”

The company recently closed the second tranche of its private placement, placing a total of 5.6 million units at $0.32 for gross proceeds of $1.8 million. Each unit consisted of one share and ½ a warrant, with each warrant exercisable at $0.50 for 2 years. Management believes this funding will take the company through the licensing stage and beyond.

In November, the company announced changes and additions to the management team, which it considered were the final pieces to ensure Supreme’s future success as a leader in the medical marijuana industry.

The shares are currently trading at $0.38, and with 76.2 million shares outstanding, the company is capitalized at $29 million. For more information, please visit the company’s website, www.supreme.ca, call 604-674-2191 or email [email protected].

About InvestmentPitch

InvestmentPitch.com, a multimedia company that provides a combined solution for creating and hosting financial video content, and distributing it across multiple platforms to investors and financial professionals, specializes in producing short three minute videos based on significant news releases and research reports.

CONTACT:
InvestmentPitch.com
Barry Morgan, CFO
[email protected]

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , ,
Posted in Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on Supreme Pharmaceuticals Completes Upgrades on Marijuana Greenhouse Facility and Awaits Pre-License Inspection by Health Canada – Video News Alert on InvestmentPitch.com

Lexaria Closes 51% Acquisition of PoViva Tea, LLC

Posted by AGORACOM-JC at 4:39 PM on Friday, December 12th, 2014

Kelowna, British Columbia–(December 12, 2014) – Lexaria, Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company”) is pleased to announce it has closed the 51% acquisition of Poviva Tea, LLC.

As the final part of the closing, Lexaria has issued 119,047 restricted common shares of the Company to each of the two founders of PoViva Tea, LLC.

All issued shares will be subject to a hold period, for any resale into the USA under Rule 144, of six months and one day. The share issuance is subject to normal regulatory approvals. The securities referred to herein will not be or have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital. There is no assurance that and cannabidiol-based product will promote, assist, or maintain any beneficial human health conditions whatsoever. No statement herein has been evaluated by the Food and Drug Administration (FDA). PoViva products are not intended to diagnose, treat, cure or prevent any disease.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. 

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , ,
Posted in All Recent Posts, Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Closes 51% Acquisition of PoViva Tea, LLC

Supreme Completes Pre-License Upgrades at Kincardine Greenhouse

Posted by AGORACOM-JC at 9:22 AM on Friday, December 12th, 2014

VANCOUVER, BRITISH COLUMBIA–(Dec. 12, 2014) – Supreme Pharmaceuticals Inc. (the “Company”) (OTCBB:SPRWF) (CSE:SL) is pleased to report that the Company has completed the security and infrastructure upgrades at the hybrid industrial greenhouse facility in Kincardine, Ontario (the “Facility“) and is ready for the Health Canada pre-license inspection of the Facility.

Since the acquisition of the 342,000 sq. ft. facility in May 2014, the Company has spent approximately $4M in upgrades to transform the Facility from an out-of use tomato greenhouse to a highly secured, state-of-the-art, automated medical marijuana facility. These upgrades include a level 9 security vault capable of storing up to $150 million of dried marijuana, a sophisticated digital security system including intrusion detection and visual surveillance, as well as sanitation and automation, all which meets or exceeds the regulatory requirements set by Health Canada.

The Company and its management team have carefully planned the upgrades of the Facility to provide an optimal environment to manufacture high quality, low-cost medical marijuana. If successful in obtaining the license to produce medical marijuana subsequent to the pre-license inspection, the Company expects to immediately commence growing in its first completed phase of the Facility. Subsequent phases of the Facility are expected to be built out later in 2015 which will increase the productive capacity of the Facility. No date has been set yet for the Health Canada inspection.

John Fowler, the Company’s Director of Operations, stated: “The construction thus far has been a massive undertaking for us. We are excited to move forward in the licensing process and stay on track with our goal of providing high-quality, low-cost medical marijuana in the coming months.”

FORWARD-LOOKING INFORMATION

This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the obtaining of a grow license, as well as the Company’s corporate strategy. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company, including, without limitation, the Company’s ability to carry out its business plan following the issuance of the required licenses by Health Canada. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.

Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to identify and complete additional suitable acquisitions to further the Company’s growth as well as risks associated with the medical marijuana industry in general such as operational risks in development and production delays or changes in plans with respect to development projects or capital expenditures; the uncertainty of the capital markets; the uncertainty of receiving the required licenses, production, costs and expenses; health, safety and environmental risks; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of the potential market; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals and changes in legislation, including but not limited to tax laws and related regulations. Accordingly, readers should not place undue reliance on the forward‐looking statements, timelines and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive.

The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws or the Canadian Securities Exchange. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.

Supreme Pharmaceuticals Inc.
Investor Relations
430 – 580 Hornby Street, Vancouver BC, V6C 3B6
(604) 674-2191
[email protected]
www.supreme.ca

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , , ,
Posted in Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on Supreme Completes Pre-License Upgrades at Kincardine Greenhouse

Enertopia Provides Burlington MMPR Update

Posted by AGORACOM-JC at 8:23 AM on Tuesday, December 9th, 2014

VANCOUVER, BC / December 9, 2014 / Enertopia Corporation (ENRT-OTCBB) (TOP-CSE) (the “Company” or “Enertopia”) is pleased to announce that Health Canada has advised the Company that the Burlington, Ontario application has advanced to the Enhanced Screening Stage of the application process.

The company is pleased to advise shareholders that its license application with joint venture partner, Lexaria Corp (LXRP), submitted for licensed producer in July 2014 is now at the Enhanced Screening process. Ontario Operations Manager Mr. Donald Shaxon is the responsible person in charge of the Burlington JV.

The Burlington Joint Venture with Lexaria Corp has applied to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49% as disclosed on April 9, 2014 in Enertopia’s press release #201424 and press release #201439.

The Burlington JV has requested a Ready to build letter from Health Canada once the application has made it through step 4 of the approval process.

For those not familiar with the Health Canada process for becoming a licensed producer, below are the levels to be reached through the application process. Note there are no specific process times for each step:

Step 1: Preliminary Screening (Completed)
Step 2: Enhanced Screening (Underway)
Step 3: Security Clearance
Step 4: Review
Step 5: Ready to build letter (if required by applicant)
Step 6: Pre-licence inspection
Step 7: Licensing

The Joint Venture (JV) has been active in the local community and has received very good community and media support. The JV also met with the local policing authority and upon licensing by Health Canada we have proposed that the local police could conduct security and swat team training at the facility. We are very pleased to be working closely with law enforcement and look forward to their insights in preventative and proactive security measures.

On November 24, 2014 Health Canada updated the number of Licensed Producers to grow and sell Marijuana to 14 and the number of Licensed Producers to grow Marijuana at 8 for a current total of 22 Licensed Producers in Canada.

“Enertopia looks forward to the next steps in the application process and receiving a letter to build in 2015. In 2015 Enertopia we will be launching education and wellness seminars to help educate the public and medical community on the responsible and educated uses of Medical Marijuana” Stated President / CEO Robert McAllister.

About Enertopia

Enertopia’s shares are quoted in Canada with symbol TOP and in the United States with symbol ENRT. For additional information, please visit www.enertopia.com or call

Clark Kent, Media Inquiries: (647) 519-2646

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, potential licensing and financing of its medical marihuana projects, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions that are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements., foreign exchange and other financial markets; changes of the interest rates on borrowings; hedging activities; changes in commodity prices; changes in the investments and exploration expenditure levels; litigation; legislation; environmental, judicial, regulatory, political and competitive developments in areas in which Enertopia Corporation operates. The User should refer to the risk disclosures set out in the periodic reports and other disclosure documents filed by Enertopia Corporation from time to time with regulatory authorities. There is no assurance that the Burlington Joint Venture will obtain a license under MMPR and or that the Company will receive a letter to build in 2015 or be able to obtain future financings.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , ,
Posted in Enertopia, Enertopia Corp., Medical Marijuana Stocks | Comments Off on Enertopia Provides Burlington MMPR Update

Lexaria Updates Burlington License Application

Posted by AGORACOM-JC at 8:10 AM on Tuesday, December 9th, 2014

Kelowna, British Columbia — (December 9, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) is pleased to announce progress on the Burlington, Ontario MMPR license application.

Health Canada has advised our joint venture partner Enertopia Corp (ENRT) that the Burlington, Ontario application has advanced to the Enhanced Screening Stage of the application process. The Burlington Joint Venture with Enertopia Corp originally applied in July 2014 to produce 10,000kg of Medical Marihuana per year under its Licensed Producer application. Enertopia has 51% interest in the joint venture and Lexaria Corp 49% as earlier released.

Health Canada has noted the following steps in processing an application. Note there are no specific process times for each step:

Step 1: Preliminary Screening (Completed)
Step 2: Enhanced Screening (Underway)
Step 3: Security Clearance
Step 4: Review
Step 5: Ready to build letter (if required by applicant)
Step 6: Pre-licence inspection
Step 7: Licensing

The current application is thorough and has been considerably improved by improvements made during the Preliminary Screening process, which has now been completed. The Burlington JV has requested a Ready To Build letter from Health Canada once the application has completed step 4 of the approval process.

The Joint Venture (JV) has been active in the local community and has received very good community and media support. The JV also met with the local policing authority and upon licensing by Health Canada we have proposed that the local police could conduct security and swat team training at the facility. We are very pleased to be working closely with law enforcement and look forward to their insights in preventative and proactive security measures.

Lexaria thanks its managers and its consultants for their dedication and hard work in advancing the license application to date.

On November 24, 2014 Health Canada updated the number of Licensed Producers to sell Marijuana to 14 and the number of Licensed Producers to grow Marijuana at 8 for a current total of 22 Licensed Producers in Canada.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for opportunities that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana or alternative health businesses will provide any benefit to Lexaria. The Company makes no human health claims related to cannabinoids derived from any source.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Start your small cap medical marijuana research in the AGORACOM Small Cap 
Medical Marijuana Stocks Gateway: 
http://agoracom.com/portal/Small%20Cap%20Medical%20Marijuana%20Stocks

Tags: , , , , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Updates Burlington License Application

Mazorro Receives Conditional Approval of Change of Business and Name Change

Posted by AGORACOM-JC at 4:36 PM on Wednesday, December 3rd, 2014

OTTAWA, ONTARIO–(Dec. 3, 2014) – Mazorro Resources Inc. (the “Company“) (CSE:MZO)(FRANKFURT:JAM) announces that it has received the conditional approval of the Canadian Securities Exchange (the “CSE“) for its proposed change of business from mineral resource exploration to the medical marijuana industry (the “Change of Business“) and its change of name to “GrowPros Cannabis Inc. / Entreprise GrowPros cannabis inc.” (the “Name Change“) upon receipt of necessary shareholder approval in respect thereof and completion of the three-cornered amalgamation with GrowPros MMP Inc., previously announced on November 6, 2014 (the “Amalgamation“).

The Company has filed an updated Form 2A listing statement under its profile on the CSE website and on SEDAR at www.sedar.com that provides additional disclosure of the terms of the Amalgamation, the Company’s proposed new business, and the related risk factors.

The Company expects that the CSE will publish a bulletin shortly to announce the resumption of trading of the Company’s common shares (the “Common Shares“) on the CSE at the opening of trading on December 4, 2014. The trading symbol “MZO” will remain the same until completion of the Amalgamation and the Name Change, following which the Common Shares will trade on the CSE under the symbol “GCI”.

Completion of the Amalgamation, the Change of Business, and the Name Change, remain subject to a number of conditions, including, but not limited to, receipt of necessary shareholder approvals in respect thereof and satisfaction of standard closing conditions for transactions of this nature.

The special meeting of the Company’s shareholders that was called to seek the requisite approval for the Change of Business and the Name Change, among other items, has been postponed and will now be held on December 29, 2014 (the “Special Meeting“). A notice of meeting, management information circular, and form of proxy in respect of the Special Meeting will be sent to shareholders and is available under the Company’s profile on the CSE website and on SEDAR.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to complete the Amalgamation and Change of Business, failure to obtain sufficient financing, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Any forward-looking statement speaks only as of the date on which it is made and except as may be required by applicable securities laws. The Company disclaims any intent or obligation to update any forward-looking statement.

Mazorro Resources Inc.
Andre Audet
Interim President, CEO, and CFO
(613) 241-2332

Tags: , , , , ,
Posted in GrowPros Cannabis Inc., Medical Marijuana Stocks | Comments Off on Mazorro Receives Conditional Approval of Change of Business and Name Change

Lexaria Enters Agreement to Sell Belmont Lake Oil Assets

Posted by AGORACOM-JC at 8:09 AM on Monday, December 1st, 2014

Kelowna, British Columbia–(December 1, 2014) – Lexaria Corp. (OTCQB: LXRP) (CSE: LXX) (the “Company” or “Lexaria”) announces it has entered an agreement to sell all its Belmont Lake oil assets in an all-cash transaction of $1.4 million to Cloudstream Belmont Lake, LP, of Houston Texas. The transaction is in the process of closing.

Lexaria is using the proceeds of the sale to retire all corporate debt, and to further pursue its entry into legal medical marijuana in Canada, and into Cannabidiol-fortified products in the USA, in those jurisdictions where it is legal to do so. Lexaria will be debt-free for the first time since 2007 and will not need to make monthly interest or principal payments for the first time in roughly 7 years.

“It was not easy to sell our minority interests in the oilfield in the environment of dropping oil prices this year,” said Chris Bunka, CEO of Lexaria. “This lump-sum cash infusion enables us to execute our business plan in the health and wellness sectors more aggressively than we were otherwise able.”

Lexaria has been in discussions with a number of interested parties over a period of several months, as it worked to obtain the best terms and conditions possible in the oil field sale for its shareholders, and is confident it has obtained the best price possible in the current environment.

Lexaria has refined its business model in order to be as active as possible within the confines of presently legal CBD-based industry sectors, and the sale of the Belmont Lake Oil Field significantly accelerates our ability to pursue this market as aggressively as possible. The Company believes its potential growth rate in the CBD sector exceeds that which was possible at the Belmont Lake Oil Field, and the timing of this asset sale is virtually perfectly meshed with the Company’s plans for growth.

Following the recent acquisition of PoViva Tea; the Belmont Lake oilfield asset sale; and the retirement of all corporate debt, Lexaria expects to retain a cash balance of approximately US$1 million. Lexaria has no plans for any corporate financing at this time.

About Lexaria

Lexaria’s shares are quoted in the USA with symbol LXRP and in Canada with symbol LXX. The company searches for projects that could provide potential above-market returns.

To learn more about Lexaria Corp. visit www.lexariaenergy.com.

FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Corp.
Chris Bunka
Chairman & CEO
(250) 765-6424

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Access to capital, or lack thereof, is a major risk and there is no assurance that the Company will be able to raise required working capital. Current oil and gas production rates may not be sustainable and targeted production rates may not occur. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that the medical marijuana, CBD sector, or alternative health businesses will provide any benefit to Lexaria, or that the Company will experience any growth through participation in these sectors. There is no assurance that existing capital is sufficient for the Company’s needs or that it will need to attempt to raise additional capital.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Tags: , ,
Posted in Lexaria Corp., Medical Marijuana Stocks | Comments Off on Lexaria Enters Agreement to Sell Belmont Lake Oil Assets

INTERVIEW: Supreme (SL:CSE) Discusses Construction Progress at 342,000 SQF. Medical Marijuana Production Facility

Posted by AGORACOM-JC at 8:22 PM on Tuesday, November 25th, 2014

Supreme Discusses Progress of 342K sqf. Medical Marijuana Production Facility

WATCH INTERVIEW NOW!

  • Significant progress made at its 342,000 square foot greenhouse facility located in Kincardine, Ontario
  • Moving quickly to implement its proposed plan to produce up to 24,000,000 grams of medical marijuana
  • Recently completed $1.7M financing
  • Received conditional pre-approval letter from Health Canada

Supreme is a Canadian-owned and operated company whose mission is to enhance the quality of life for their patients and clients by producing sun-grown medical marijuana of the highest standards, quality and value. The company’s vision is a client-centered, environmentally-friendly and affordable medical marijuana marketplace sustained by the marriage of commercial agriculture and traditional growing.

Hub On AGORACOM / Corporate Profile / Watch Interview!

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Supreme Pharmaceuticals Inc | Comments Off on INTERVIEW: Supreme (SL:CSE) Discusses Construction Progress at 342,000 SQF. Medical Marijuana Production Facility

« Older Entries
Newer Entries »